Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

BACKGROUND: Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients. METHODS: In this...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2013
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3658508/
https://ncbi.nlm.nih.gov/pubmed/23612453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.183
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller